Current Neurologist-Reported Patient Share for Tecfidera Exceeds that of Genzyme’s Aubagio and Novartis’s Gilenya Combined, According to Findings from Decision Resources Group
Story Source: The above story is based on materials provided by BIOTRENDS RESEARCH GROUP
Note: Materials may be edited for content and length
